ADC · HER2+ 유방암

5개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved5 programs
ADCStandard DatabasestaleDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 2

T-DXd, DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (T-DXd, DS-8201a))

Advanced Breast Cancer; Advanced Breast Carcinoma · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 122Status Recruiting
ADCStandard DatabasestaleRocheDM1 via butelase-1 with ABD…Phase 3

T-DM1 (Trastuzumab emtansine, Trastuzumab emtansine (T-DM1))

Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants · HER2

#HER2#ADC#Phase3#Popular#antibody-drug-conjugate+4
Trials 59Status Recruiting
ADCStandard DatabasestaleMacroGenicsPhase 2

vobramitamab duocarmazine (vobramitamab duocarmazine)

Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#antibody-drug-conjugate#SquamousCellCarcinomaofHeadandNe+2
Trials 3Status Discontinued
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab vedotin + Sintilimab + Multimodality radiotherapy)

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveAdvancedGastricCanc+1
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Megestrol Acetate + Trastuzumab Deruxtecan)

Advanced/Metastatic Breast Cancer; HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer · HER2

#HER2#ADC#Phase3#antibody-drug-conjugate#Advanced+3
Trials 1Status Recruiting